Phase i study of camrelizumab in patients with advanced solid tumors

HIGHLIGHTS

• who: Yuxiang Ma from the (UNIVERSITY) have published the paper: Phase I study of camrelizumab in patients with advanced solid tumors, in the Journal: (JOURNAL) of 28/09/2022
• what: The study evaluated the impact of continuous peripheral blood RO on the efficacy of camrelizumab although it may not fully
• future: Studies including exposure-response studies are needed to better inform clinical dosing strategies.

SUMMARY

Received reflect the intra-tumor and differentiated non-activated T_cells in RO, it still provides a better understanding of the therapeutic efficacy of camrelizumab . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.